Troponin Surveillance for Myocardial Injury After Noncardiac Surgery
A common, largely silent complication is easy to detect after surgery — but detecting injury and improving outcomes are not the same question.
One-Minute Takeaway
- Troponin surveillance uncovers myocardial injury after noncardiac surgery (MINS), a common and largely silent complication: in the BASEL-PMI screening cohort, injury followed 16% of surgeries in higher-risk patients, and only about one in five had any ischaemic symptom. [Verified]
- The prognostic signal is strong. Thirty-day mortality was 8.9% with injury versus 1.5% without (adjusted HR 2.7, 95% CI 1.5–4.8), and MINS carried the highest population-attributable risk (34%) of the perioperative complications studied. [Verified]
- Guidelines now converge on surveillance for higher-risk patients before intermediate- or high-risk surgery, but differ in strength — from routine (Canadian) to Class I in defined groups (European) to “consider” (2024 US). [Verified]
- The central gap: only one randomised trial (MANAGE) has tested treating detected injury. Dabigatran lowered major vascular events (HR 0.72, 95% CI 0.55–0.93), but 46% stopped the drug and it was not compared against standard aspirin and statin care. [Verified]
- No trial has shown that screening itself improves outcomes; the case rests on prognosis plus mostly observational management data. [Secondary]
Why Troponin Surveillance Matters
Myocardial injury after noncardiac surgery (MINS) is ischaemic myocardial injury marked by a rise in cardiac troponin within roughly 30 days of surgery, with or without symptoms. It is common, and it is easy to miss.
The reason it is missed is that it is usually silent. In the VISION cohort of adults having inpatient surgery, the large majority of patients with injury reported no ischaemic symptoms, so without routine testing most cases were never recognised. Postoperative analgesia and the surgical context plausibly mask the usual warning signs.
Silence does not mean safety. Injury detectable only by troponin was associated with a substantial rise in short- and long-term mortality across large international cohorts. Because roughly 200 million adults undergo major surgery each year — of whom an estimated 8 million sustain MINS — even a modest per-patient risk becomes a large absolute burden.
That combination — frequent, largely silent, and prognostically important — is the argument for surveillance. If a condition this consequential is invisible without a test, the case for testing at least the patients most likely to have it is intuitive. Whether intuition matches outcome benefit is the harder question this review returns to.
What the Guidelines Recommend About Troponin Surveillance
Three major bodies have taken positions on postoperative troponin surveillance. They point in the same direction — testing higher-risk patients having higher-risk surgery — but differ in how firmly they recommend it.
Canadian Cardiovascular Society (2017)
The CCS guideline recommends preoperative BNP or NT-proBNP in patients aged 65 or older, those 45–64 with significant cardiovascular disease, or those with a Revised Cardiac Risk Index factor. When the natriuretic peptide is elevated — or in these patients when it is unavailable — it recommends daily troponin measurement across the first postoperative days. In practice this amounts to routine surveillance for at-risk inpatients, paired with an antiplatelet and a statin when injury is found.
European Society of Cardiology (2022)
The ESC guideline recommends high-sensitivity cardiac troponin T or I before, and at 24 and 48 hours after, intermediate- or high-risk surgery in patients with known cardiovascular disease or risk factors including age 65 or older (Class I, level of evidence B). It explicitly advises against routine biomarker testing in low-risk patients having low- or intermediate-risk surgery (Class III, level of evidence B).
United States: AHA/ACC multisociety (2024)
The 2024 US guideline now includes a recommendation to consider postoperative troponin surveillance in higher-risk patients. That is a shift from the 2014 guideline it supersedes, which reserved troponin testing for patients with signs or symptoms of ischaemia. The change moves the US position closer to the Canadian and European ones, while framing surveillance as something to consider rather than to perform routinely.
Where they agree, and where they don’t
All three target the same population — older patients, established cardiovascular disease or risk factors, and intermediate- or high-risk inpatient surgery — and all three discourage indiscriminate testing of low-risk patients. The disagreement is one of strength, not direction: routine, versus Class I in defined groups, versus “consider.”
Evidence Reviewed
The recommendations above rest on a consistent body of prognostic cohort data and a single interventional trial. The table compares the studies that anchor the surveillance question, spanning the evidence that injury matters (cohorts) and the evidence for acting on it (one randomised trial, plus observational management data). Every figure and identifier was confirmed against a primary source for this review.
| Study / Source | Design | N | Population | Focus | Key result |
|---|---|---|---|---|---|
| Botto 2014 Anesthesiology | Prospective cohort | 15,065 | Adults ≥45y, inpatient noncardiac surgery | Defining MINS criteria and prognosis | MINS in 8.0% (peak TnT ≥0.03 ng/mL, ischaemic); adjusted HR 3.87 (95% CI 2.96–5.08) for 30-day death; highest population-attributable risk, 34.0% (95% CI 26.6–41.5) V |
| VISION 2017 JAMA | Prospective cohort | 21,842 | Adults ≥45y, inpatient noncardiac surgery | High-sensitivity TnT and 30-day mortality | Peak postoperative hs-TnT independently associated with 30-day death (266 deaths, 1.2%); association held for injury without ischaemic features V |
| BASEL-PMI 2018 Circulation | Prospective screening cohort | 2,018 (2,546 surgeries) | Higher-risk patients, stay ≥24h | Systematic hs-TnT screening | Injury after 16% of surgeries (95% CI 14–17%); 30-day mortality 8.9% vs 1.5%; adjusted HR 2.7 (95% CI 1.5–4.8); 1-year 22.5% vs 9.3% V |
| MANAGE 2018 Lancet | Randomised, placebo-controlled trial | 1,754 | Adults with MINS within 35 days | Dabigatran 110 mg twice daily vs placebo | Major vascular composite 97/877 (11%) vs 133/877 (15%); HR 0.72 (95% CI 0.55–0.93); safety composite HR 0.92 (95% CI 0.55–1.53); 46% vs 43% discontinued study drug V |
| Park 2020 Sci Rep | Observational cohort | 5,109 | Patients discharged after MINS | Statin at discharge vs none | 1-year mortality 6.1% vs 13.3%; HR 0.55 (95% CI 0.41–0.74); consistent after inverse-probability weighting — associative, not randomised V |
V = verified against a retrieved primary source. Designs are mixed by intent: three prognostic cohorts show that surveillance detects something dangerous; one randomised trial and one observational cohort speak to what acting on it achieves. Cohort associations use associative language; only the randomised trial supports causal claims.
Key Changes and Their Basis
The drift of guidelines toward surveillance rests on three findings that reappear across independent cohorts. Injury is common. It is mostly silent. And it independently tracks with death, from 30 days out to a year.
Assay evolution explains part of the picture. High-sensitivity troponin assays lowered detection thresholds and sharpened case-finding, which is why later cohorts using an absolute high-sensitivity rise report incidence near 16%, while earlier work using a higher conventional threshold reported around 8%. The condition did not become more frequent; the test became more sensitive.
The 2024 US guideline’s addition of a surveillance recommendation reflects this accumulated cohort evidence. It aligns the US more closely with the Canadian and European positions than the 2014 symptom-triggered approach did, and it reframes MINS as a distinct entity worth looking for rather than a laboratory curiosity.
What did not change is the underlying logic gap. Every position rests on the prognostic strength of a positive test, not on trial evidence that finding and acting on injury changes what happens to patients. That distinction shapes the sections that follow.
Quality and Consistency of the Evidence
The evidence is strong where it concerns prognosis and weaker where it concerns action. Rating each strand by the strength and consistency of its supporting data:
-
Prognostic association between postoperative troponin and mortality.
Multiple large, international, prospective cohorts report a concordant, independent, dose-graded association. This is the most consistent finding in the field. -
Benefit of anticoagulation after detected injury.
One randomised trial (MANAGE) showed fewer major vascular events with dabigatran, but with high drug discontinuation and no comparison against standard secondary-prevention care. -
Benefit of intensified medical therapy (aspirin, statin) after detection.
Supported by observational and post-hoc analyses and by proven benefit in non-surgical vascular disease, but not by a dedicated randomised trial in MINS. -
That surveillance itself improves patient outcomes.
No randomised comparison of surveillance versus no surveillance exists; observational implementation data are mixed, with at least one study showing no change in detection, infarction, or mortality after a national guideline.
What the Evidence Does Not Show
The prognostic case is settled; the actionability case is not. Several specific gaps sit between “troponin surveillance detects injury” and “troponin surveillance helps patients.”
No screening trial. No study has randomised patients to surveillance versus no surveillance and measured a patient-important outcome. The claim that screening improves outcomes is therefore indirect — inferred from prognosis plus the effect of downstream treatment, not demonstrated directly.
The one treatment trial has limits. MANAGE showed that dabigatran lowered major vascular events in patients with MINS (HR 0.72, 95% CI 0.55–0.93). But roughly 46% of patients discontinued the drug, it was compared with placebo rather than with the aspirin-and-statin care many such patients should already receive, and few patients underwent revascularisation — so the trial neither settles optimal therapy nor establishes that detection-plus-treatment beats usual care.
Real-world detection has not clearly moved outcomes. A single-centre Canadian study found that detection of injury, infarction, and mortality did not change after the national surveillance guideline was published, with inconsistent adherence in daily practice. Implementation and benefit are not the same thing.
Management of non-infarction injury is uncertain. Most MINS does not meet the universal definition of myocardial infarction, and the optimal drug strategy for that majority remains largely observational. A positive troponin also has a broad differential — supply–demand mismatch, pulmonary embolism, sepsis, arrhythmia — so a rise is not, on its own, a diagnosis of type 1 infarction.
Practical Implications
Read as support for clinical judgement rather than as directives, the evidence points to a small number of considerations that separate useful surveillance from reflexive testing.
- Target by pretest risk. Surveillance yields most where injury is most likely and consequential — older patients, known cardiovascular disease or risk factors, and intermediate- or high-risk inpatient surgery. This is the population all three guidelines converge on, and the group in which a positive result carries the clearest prognostic weight.
- Test at defined times. The guideline model is a preoperative baseline where indicated, then measurement in the first days after surgery (for example at 24 and 48 hours, or across postoperative days 0–3). A baseline matters because a proportion of patients have an elevated preoperative value that changes interpretation.
- Read a positive result as a differential, not a diagnosis. A troponin rise reflects injury, not necessarily plaque rupture. Before labelling infarction, look for treatable contributors — hypotension, anaemia, tachyarrhythmia, sepsis, pulmonary embolism — and manage the cause.
- Where injury is ischaemic, apply secondary prevention. Absent bleeding risk, aspirin and a statin are reasonable, supported by observational data — a post-hoc POISE analysis linked aspirin (adjusted OR 0.54, 95% CI 0.29–0.99) and statin therapy (adjusted OR 0.26, 95% CI 0.13–0.54) to lower 30-day mortality — and by established benefit in vascular disease. Dabigatran can be considered where available, weighing the MANAGE caveats.
- Only screen if you will act and follow up. The value of detection depends entirely on what follows it: evaluation, treatment where warranted, and arranged cardiovascular follow-up. Surveillance without a downstream plan generates prognostic information no one uses.
Evidence Grade and Bottom Line
Prognosis: High Screening → outcomes: Low Post-detection treatment: Low–Moderate
Bottom line
- Troponin surveillance reliably uncovers a common, mostly silent, prognostically serious complication that would otherwise be missed in most patients who have it.
- Guidelines increasingly support surveillance for higher-risk patients before higher-risk surgery, differing in strength from routine to “consider,” and agreeing that low-risk patients should not be tested indiscriminately.
- What remains unproven is that screening improves outcomes. Only one randomised trial has tested treating detected injury, with meaningful caveats, and no trial has tested surveillance itself against a patient-important endpoint.
- The defensible position: surveillance is reasonable in higher-risk patients when it is coupled with a plan to evaluate and manage positive results — not as a reflex test, and not in low-risk patients.
Article Information and References
- Botto F, Alonso-Coello P, Chan MT, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology. 2014;120(3):564–578. DOI: https://doi.org/10.1097/ALN.0000000000000113
- Writing Committee for the VISION Study Investigators; Devereaux PJ, Biccard BM, Sigamani A, et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2017;317(16):1642–1651. DOI: https://doi.org/10.1001/jama.2017.4360
- Puelacher C, Lurati Buse G, Seeberger D, et al; BASEL-PMI Investigators. Perioperative myocardial injury after noncardiac surgery: incidence, mortality, and characterization. Circulation. 2018;137(12):1221–1232. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.030114
- Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018;391(10137):2325–2334. DOI: https://doi.org/10.1016/S0140-6736(18)30832-8
- Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society Guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol. 2017;33(1):17–32. DOI: https://doi.org/10.1016/j.cjca.2016.09.008
- Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826–3924. DOI: https://doi.org/10.1093/eurheartj/ehac270
- Thompson A, Fleischmann KE, Smilowitz NR, et al. 2024 AHA/ACC/multisociety guideline for perioperative cardiovascular management for noncardiac surgery. Circulation. 2024;150(19):e351–e442. DOI: https://doi.org/10.1161/CIR.0000000000001285
- Ruetzler K, Smilowitz NR, Berger JS, et al. Diagnosis and management of patients with myocardial injury after noncardiac surgery: a scientific statement from the American Heart Association. Circulation. 2021;144(19):e287–e305. DOI: https://doi.org/10.1161/CIR.0000000000001024
- Park J, Kim J, Lee SH, et al. Postoperative statin treatment may be associated with improved mortality in patients with myocardial injury after noncardiac surgery. Sci Rep. 2020;10:11616. DOI: https://doi.org/10.1038/s41598-020-68511-3